Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1891 1
1946 2
1948 1
1949 2
1950 1
1951 1
1952 3
1953 1
1955 1
1956 1
1957 2
1958 1
1960 1
1962 1
1964 2
1965 3
1966 1
1969 1
1970 3
1972 2
1973 3
1974 1
1975 2
1976 1
1977 3
1978 7
1979 2
1980 6
1981 8
1982 1
1983 2
1984 6
1985 8
1986 3
1987 6
1988 7
1989 10
1990 10
1991 5
1992 10
1993 12
1994 18
1995 13
1996 17
1997 18
1998 23
1999 13
2000 23
2001 36
2002 34
2003 28
2004 26
2005 46
2006 56
2007 47
2008 33
2009 44
2010 47
2011 43
2012 34
2013 44
2014 34
2015 34
2016 51
2017 35
2018 43
2019 40
2020 42
2021 62
2022 29
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

1,080 results
Results by year
Filters applied: . Clear all
Page 1
Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. Myers JA, et al. Among authors: miller js. Nat Rev Clin Oncol. 2021 Feb;18(2):85-100. doi: 10.1038/s41571-020-0426-7. Epub 2020 Sep 15. Nat Rev Clin Oncol. 2021. PMID: 32934330 Free PMC article. Review.
An updated advance of autoantibodies in autoimmune diseases.
Xiao ZX, Miller JS, Zheng SG. Xiao ZX, et al. Among authors: miller js. Autoimmun Rev. 2021 Feb;20(2):102743. doi: 10.1016/j.autrev.2020.102743. Epub 2020 Dec 14. Autoimmun Rev. 2021. PMID: 33333232 Review.
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, Tuininga K, Zhang B, Wu CY, Kodal B, Khaw M, Bendzick L, Rogers P, Ge MQ, Bonello G, Meza M, Felices M, Huffman J, Dailey T, Lee TT, Walcheck B, Malmberg KJ, Blazar BR, Bryceson YT, Valamehr B, Miller JS, Cichocki F. Woan KV, et al. Among authors: miller js. Cell Stem Cell. 2021 Dec 2;28(12):2062-2075.e5. doi: 10.1016/j.stem.2021.08.013. Epub 2021 Sep 14. Cell Stem Cell. 2021. PMID: 34525347 Free PMC article.
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Cichocki F, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H, Tuininga K, Felices M, Davis ZB, Bendzick L, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Robbins DL, Lee TT, Kaufman DS, Blazar BR, Valamehr B, Miller JS. Cichocki F, et al. Among authors: miller js. Sci Transl Med. 2020 Nov 4;12(568):eaaz5618. doi: 10.1126/scitranslmed.aaz5618. Sci Transl Med. 2020. PMID: 33148626 Free PMC article.
Human NK Cell Development: One Road or Many?
Cichocki F, Grzywacz B, Miller JS. Cichocki F, et al. Among authors: miller js. Front Immunol. 2019 Aug 29;10:2078. doi: 10.3389/fimmu.2019.02078. eCollection 2019. Front Immunol. 2019. PMID: 31555287 Free PMC article. Review.
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Berrien-Elliott MM, et al. Among authors: miller js. Blood. 2022 Feb 24;139(8):1177-1183. doi: 10.1182/blood.2021011532. Blood. 2022. PMID: 34797911 Clinical Trial.
1,080 results